-
摘要: 嗜铬细胞瘤/副神经节瘤(pheochromocytoma and paranganglioma, PPGL)患者由于过度分泌儿茶酚胺, 因而有较高的继发性高血压发生率和死亡率。大约1/4的PPGL具有侵袭转移性, 这类不能切除的转移性病灶的治疗方案包括131I-间碘苄胍核素治疗、放疗和化疗, 但此类治疗也只能控制肿瘤生长和抑制激素水平。过去10年, PPGL的临床和分子机制研究均取得了诸多进展, 然而预后判断和治疗仍然是临床实践中最大的挑战。转移性PPGL患者的自然病史往往未知, 其预后也不尽相同, 目前诊断依然依赖于转移灶的存在, 因此通常诊断时已是晚期。有研究对患者的临床和分子特征、导致转移性PPGL的特定信号通路的改变进行了探索, 以期随着核素治疗、放疗联合分子靶向治疗的发展, 提高该病的临床预后。Abstract: Hypersecretion of catecholamines from pheochromocytoma and paraganglioma(PPGL) is associated with high morbidity and mortality, even when the tumors are benign. Up to 25% of PPGL are associated with germline mutations in susceptible genes. About one-quarter is metastatic, defined by the presence of distant metastases. Treatment options for unresectable metastatic disease, including chemotherapy, 131I-MIBG, and radiation, can offer limited tumor and hormone control, although none are curative. Over the past 10 years, substantial progress has been made toward understanding the clinical aspects and molecular origins of PPGL. Nevertheless, predicting and managing malignancy remains the biggest challenge in clinical practice. The natural history of patients with metastatic PPGL has not yet been described, and their prognosis varies. Currently, the diagnosis of metastatic PPGL relies on the presence of metastases, and by then, the disease is usually advanced. A better understanding of the clinical and molecular characteristics of patients with metastatic PPGL has spurred several prospective clinical trials. A deeper understanding of the alteration of the specific molecular pathways causing metastatic PPGL might hopefully lead in the future to the development of radiotherapy and multiple molecular-targeted therapies to treat it successfully.
-
Key words:
- pheochromocytoma /
- paraganglioma /
- metastatic /
- catecholamine /
- prognosis
利益冲突 无 -
表 1 确诊并行手术治疗后5年PPGL患者的转移复发风险[11]
组别 出现新发复发转移的风险[% (95% CI)] 嗜铬细胞瘤 8(6~11) 胸腹盆副神经节瘤 18(11~31) 头颈部副神经节瘤 25(11~57) 确诊时年龄≥20岁 9(7~12) 确诊时年龄<20岁 27(15~51) 非家族遗传/无基因突变 7(5~11) 家族遗传综合征/基因突变 17(12~24) 肿瘤最大直径≤5 cm 10(7~14) 肿瘤最大直径>5 cm 26(6~100) 总体 10(8~14) PPGL:转移性嗜铬细胞瘤/副神经节瘤 -
[1] Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma:an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2014, 99:1915-1942. http://smartsearch.nstl.gov.cn/paper_detail.html?id=8b6ce9d9147fa1e064f8d36bc2e7caa0 [2] Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromo-cytoma and paraganglioma[J]. Clin Chem, 2014, 60:1486-1499. https://pubmed.ncbi.nlm.nih.gov/25332315/ [3] Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma:from genetics to personalized medicine[J]. Nat Rev Endocrinol, 2015, 11:101-111. http://europepmc.org/abstract/med/25385035 [4] Hamidi O, Young WF Jr, Gruber L, et al.Outcomes of patients with metastatic phaeochromocytoma and paraganglioma:A systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2017, 87:440-450. doi: 10.1111/cen.13434/abstract [5] Cascón A, Comino-Méndez I, Currás-Freixes M, et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene[J]. J Natl Cancer Inst, 2015, 107. pii: djv053. [6] Feral CC, Tissot FS, Tosello L, et al. 18F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma:relation to genotype and amino acid transport system L[J]. Eur J Nucl Med Mol Imaging, 2017, 44:812-821. doi: 10.1007/s00259-016-3586-z [7] Rafat C, Zinzindohoue F, Hernigou A, et al. Peritoneal implantation of pheochromocytoma following tumour capsule rupture during surgery[J]. J Clin Endocrinol Metab, 2014, 99:E2681-5. https://www.ncbi.nlm.nih.gov/pubmed/25188716 [8] Pang Y, Liu Y, Pacak K, et al.Pheochromocytomas and Paragangliomas:From Genetic Diversity to Targeted Therapies[J].Cancers (Basel), 2019, 11. pii:E436. http://www.ncbi.nlm.nih.gov/pubmed/30925729 [9] Wu D, Tischler AS, Lloyd RV, et al. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score[J]. Am J Surg Pathol, 2009, 33:599-608. http://www.ncbi.nlm.nih.gov/pubmed/19145205 [10] Agarwal A, Mehrotra PK, Jain M, et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS):can they predict malignancy?[J]. World J Surg, 2010, 34:3022-3028. https://pubmed.ncbi.nlm.nih.gov/20703467/ [11] Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma[J]. Endocr Relat Cancer, 2014, 21:405-414. http://europepmc.org/abstract/med/24521857 [12] Rufini V, Treglia G, Castaldi P, et al. Comparison of metaiodobenzyl-guanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma:a systematic review[J]. Q J Nucl Med Mol Imaging, 2013, 57:122-133. http://europepmc.org/abstract/med/23822989 [13] 张迎强, 陈黎波, 李方, 等. 131I-MIBG显像诊断嗜铬细胞瘤[J].中国医学影像技术, 2009, 25:1283-1285. http://www.cnki.com.cn/Article/CJFDTotal-ZYXX200907063.htm [14] Nakamoto R, Nakamoto Y, Ishimori T, et al. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma[J]. Clin Nucl Med, 2016, 41:e465-e472. [15] Feral CC, Tissot FS, Tosello L, et al. 18F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma:relation to genotype and amino acid transport system L[J]. Eur J Nucl Med Mol Imaging, 2017, 44:812-821. doi: 10.1007/s00259-016-3586-z [16] Noto RB, Pryma DA, Jensen J. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma[J].J Clin Endocrinol Metab, 2018, 103:213-220. http://smartsearch.nstl.gov.cn/paper_detail.html?id=14676939153cef22f8356c288aaa2c1e [17] Asai S, Katabami T, Tsuiki M, et al.Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas[J]. Horm Cancer, 2017, 8:108-118. doi: 10.1007/s12672-017-0284-7 [18] Edo N, Yamamoto T, Takahashi S, et al.Optimizing Hemodynamics with Transcatheter Arterial Embolization in Adrenal Pheochromocytoma Rupture[J]. Intern Med, 2018, 57:1873-1878. http://europepmc.org/articles/PMC6064710/ [19] Brancíková D, Mechl Z, Adam Z, et al. Patient with inoperable pheochromocytoma[J].Curr Oncol, 2015, 22:e216-9. [20] Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma[J]. J Clin Endocrinol Metab, 2009, 94:5-9. http://www.ncbi.nlm.nih.gov/pubmed/19001511 [21] Lee M, Minaskan N, Wiedemann T, et al. Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo[J]. Endocr Relat Cancer, 2017, 24:1-15. http://smartsearch.nstl.gov.cn/paper_detail.html?id=8da161c0e6423bf91641145af9ac91c4 [22] Deng JH, Li HZ, Zhang YS, et al.Functional paragangliomas of the urinary bladder:report of 9 cases[J]. Chin J Cancer, 2010, 29:729-734. https://www.researchgate.net/publication/45388285_Functional_paragangliomas_of_the_urinary_bladder_A_report_of_9_cases [23] Parikh PP, Rubio GA, Farra JC, et al.Nationwide review of hormonally active adrenal tumors highlights high morbidity in pheochromocytoma[J]. J Surg Res, 2017, 215:204-210. https://www.sciencedirect.com/science/article/pii/S0022480417302093
点击查看大图
表(1)
计量
- 文章访问数: 603
- HTML全文浏览量: 43
- PDF下载量: 269
- 被引次数: 0